Scholarlink

<p>Glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) is featured by oxidative stress and impaired bone regeneration. Alpha-2-Macroglobulin (α-2&#xa0;M) was reported to possess cytoprotective and anti-inflammatory properties, and have shown its role in alleviating GIONFH. nuclear factor erythroid 2-related factor 2 (Nrf2) was proved to mediate oxidative stress in GIONFH. We aimed to investigate whether α-2&#xa0;M attenuates GIONFH by exerting a dual osteogenic and antioxidant effect through the Akt/Nrf2 signaling pathway. We induced GIONFH model in rats and injected α-2&#xa0;M and Nrf2 inhibitor subsequently. Micro-CT and histology revealed that α-2&#xa0;M treatment prevented methylprednisolone (MPS)-induced bone loss, preserving trabecular structure and reducing empty lacunae. α-2&#xa0;M reversed the MPS-mediated suppression of Akt-Nrf2 pathway, upregulating the expression of heme oxygenase-1 (HO-1) and osteogenic markers. The Nrf2 inhibitor ML385 negated these benefits, confirming that α-2&#xa0;M mitigates GIONFH by upregulating osteogenesis and reducing oxidative stress through the Akt/Nrf2 axis. The results demonstrated that α-2&#xa0;M is a promising target for managing GIONFH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Alpha-2-macroglobulin attenuates glucocorticoid-induced osteonecrosis of the femoral head by enhancing osteogenesis and antioxidant defense via the Akt/Nrf2 signaling pathway

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Qingjian He,
  • Xin Zheng,
  • Boyun Huang,
  • Xianjie Xie,
  • Manying Lin,
  • Pengcheng Lin,
  • He Chen,
  • Jinghui Li

摘要

Glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) is featured by oxidative stress and impaired bone regeneration. Alpha-2-Macroglobulin (α-2 M) was reported to possess cytoprotective and anti-inflammatory properties, and have shown its role in alleviating GIONFH. nuclear factor erythroid 2-related factor 2 (Nrf2) was proved to mediate oxidative stress in GIONFH. We aimed to investigate whether α-2 M attenuates GIONFH by exerting a dual osteogenic and antioxidant effect through the Akt/Nrf2 signaling pathway. We induced GIONFH model in rats and injected α-2 M and Nrf2 inhibitor subsequently. Micro-CT and histology revealed that α-2 M treatment prevented methylprednisolone (MPS)-induced bone loss, preserving trabecular structure and reducing empty lacunae. α-2 M reversed the MPS-mediated suppression of Akt-Nrf2 pathway, upregulating the expression of heme oxygenase-1 (HO-1) and osteogenic markers. The Nrf2 inhibitor ML385 negated these benefits, confirming that α-2 M mitigates GIONFH by upregulating osteogenesis and reducing oxidative stress through the Akt/Nrf2 axis. The results demonstrated that α-2 M is a promising target for managing GIONFH.